Haleon offers a financially sound consumer health franchise with strong margins and a favorable risk/reward setup, but a death cross and sustained negative price momentum block near-term entry; the thesis requires a technical reversal before the asymmetric upside becomes actionable.
Thesis pillars
- Quality Margins Piotroski→Stable
- Death Cross Price Momentum↓Deteriorating
- Asymmetric Upside Risk Reward↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Haleon plc (HLN) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $8.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more
Hold if already holding. Not a fresh buy at $8.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Maintain position. Not compelling to add more. Score 5.0/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 113d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated Nov 4, 2026Recent Developments — Haleon plc
Latest news
- NEWS Jefferies Downgrades Haleon to Hold from Buy — fiscal.ai Nov 4, 2026 negative
- NEWS Goldman Sachs Removes Haleon from European Conviction List — fiscal.ai Nov 2, 2026 negative
- NEWS Haleon Sees Volume Recovery From North America, and Margins Continue to Improve - Morningstar — Morningstar Jul 30, 2026 positive
- NEWS Haleon plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:HLN) 2026-07-30 - Seeking Alpha — Seeking Alpha Jul 30, 2026 neutral
- NEWS Tranche Update on Haleon plc's Equity Buyback Plan announced on March 12, 2026. - marketscreener.com — marketscreener.com Jul 30, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-04T11:59:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Maintain position. Not compelling to add more. Analyst target $9.05 (+2.3%), stop $8.24 (−7.3%), A.R:R 0.3:1. Score 5.0/10, moderate confidence.
Analyst target: $9.05 (+2.3% upside). Analyst target $9.05 (+2.3%), stop $8.24 (−7.3%), A.R:R 0.3:1. Stop-loss: $8.24.
Analyst target reached - limited upside remaining; Weak growth; Below 200-day MA.
Haleon plc trades at a P/E of 18.0 (forward 14.6). TrendMatrix value score: 5.8/10. Verdict: Hold.
26 analysts rate HLN, with a consensus score of 4.0/5. 5 analysts publish price targets averaging $10.
What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.